Trials / Completed
CompletedNCT01817452
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- West German Study Group · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Trial to evaluate efficacy of dual blockade with two anti-HER2 agents with or without chemotherapy backbone within the ADAPT trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab | |
| DRUG | Pertuzumab | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
- First posted
- 2013-03-25
- Last updated
- 2025-02-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01817452. Inclusion in this directory is not an endorsement.